KR970064597A - 위장장애 또는 위산분해가 있는 약물의 직장투여용 조성물 - Google Patents

위장장애 또는 위산분해가 있는 약물의 직장투여용 조성물 Download PDF

Info

Publication number
KR970064597A
KR970064597A KR1019970009499A KR19970009499A KR970064597A KR 970064597 A KR970064597 A KR 970064597A KR 1019970009499 A KR1019970009499 A KR 1019970009499A KR 19970009499 A KR19970009499 A KR 19970009499A KR 970064597 A KR970064597 A KR 970064597A
Authority
KR
South Korea
Prior art keywords
composition
rectal administration
drug
gastric acid
gastrointestinal disorders
Prior art date
Application number
KR1019970009499A
Other languages
English (en)
Inventor
윤성준
유제만
최한곤
정재희
성용길
Original Assignee
황규언
동화약품공업 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 황규언, 동화약품공업 주식회사 filed Critical 황규언
Publication of KR970064597A publication Critical patent/KR970064597A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 위장장애 또는 위산분해가 있는 약물, 폴록사머 및 친수성 천연 고분자을 함유하는 직장투여용 조성물에 관한 것이다.
본 발명의 직장투여용 조성물은 겔화온도가 30-36℃이고, 겔강도와 생체부착력이 우수하여 투여전 상온에서 액체상태이고, 투여후에는 즉시 겔화되어 직장점막에 부착되어 지속적으로 머무르면서 약물을 방출하여 체외로 빠져나오거나 대장말단으로 이행되지 않으며 위장장애 또는 위산분해없이 흡수된다.

Description

위장장애 또는 위산분해가 있는 약물의 직장투여용 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 위장장애 또는 위산분해가 있는 약물 0.1-10중량부, 폴록사머 25-40중량부 및 친수성 천연 고분자 0.1-1중량부를 함유하는 직장투여용 조성물.
  2. 제1항에 있어서, 위장장애가 있는 약물이 아스피린, 아세트아미노펜, 케토르로펜, 인도메타신, 나프록센, 철분 화합물, 케토코나졸, 이트라코나졸, 에코나졸 및 세파-항생제에서 선택됨을 특징으로 하는 직장투여용 조성물.
  3. 제1항에 있어서, 위산분해가 있는 약물이 프로폭시펜, 메페리딘, 메타돈, 펜타조산, 덱사메타존, p-아미노안식향, 설폰아미드, p-아미노히푸르산, 에스트로겐, 오메프라졸, 판크레아틴, 세라티오펩티다아제, 1-도파, α-메틸도마, 하이ㅡ로코티손, 코티손, 알도스테론, 프로게스테론 및 인슐린에서 선택됨을 특징으로 하는 직장투여용 조성물.
  4. 제1항에 있어서, 플록사머가 고상타입, 액상타입 및 페이스트 타입에서 1종 또는 2종이상 선택됨을 특징으로 하는 직장투여용 조성물.
  5. 제1항에 있어서, 친수성 천연고분자가 키토산 및 알긴산 나트륨염의 천연고분자에서 단독으로 또는 혼합하여 선택됨을 특징으로 하는 직장투여용 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970009499A 1996-03-21 1997-03-20 위장장애 또는 위산분해가 있는 약물의 직장투여용 조성물 KR970064597A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19960007637 1996-03-21
KR96-7637 1996-03-21

Publications (1)

Publication Number Publication Date
KR970064597A true KR970064597A (ko) 1997-10-13

Family

ID=19453575

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970009499A KR970064597A (ko) 1996-03-21 1997-03-20 위장장애 또는 위산분해가 있는 약물의 직장투여용 조성물

Country Status (2)

Country Link
KR (1) KR970064597A (ko)
WO (1) WO1997034580A1 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1158957A4 (en) 1999-02-24 2004-12-15 Dong Wha Pharm Ind Co Ltd LIQUID SUPPOSITORY COMPOSITION FOR DICLOFENAC SODIUM
US20030204180A1 (en) * 2002-04-30 2003-10-30 Kimberly-Clark Worldwide, Inc. Temperature responsive delivery systems
US20060078616A1 (en) * 2004-08-30 2006-04-13 Georgewill Dawaye A Thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol
EP2338477A1 (en) 2009-12-15 2011-06-29 bene-Arzneimittel GmbH Suppository comprising pantoprazole
KR101003890B1 (ko) * 2010-04-14 2010-12-30 영남대학교 산학협력단 직장투여용 도세탁셀 함유 온도감응성 액상좌제 조성물
WO2012171540A1 (en) 2011-06-15 2012-12-20 Bene-Arzneimittel Gmbh Suppository comprising pantoprazole comprised in pellets with a cellulose core
DE102015112875A1 (de) * 2015-08-05 2017-02-09 Dr. Armah-Biomedica Gmbh & Co. Kg Suppositorium auf Basis einer wärme-unempfindlichen Fettmasse
EP3538132B1 (en) 2016-11-14 2020-12-30 University of Copenhagen Rectal insulin for treatment of inflammatory bowel diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1207231A (en) * 1982-08-24 1986-07-08 Hans W. Zulliger Medicated suppository
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5346703A (en) * 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
IT1255460B (it) * 1992-07-28 1995-11-02 Poli Ind Chimica Spa Composizioni farmaceutiche in forma di microemulsioni o di dispersioni liposomiali bioadesive per la somministrazione transmucosale di sostanze peptidiche e di proteine farmacologicamente attive
FR2694194B1 (fr) * 1992-07-31 1994-11-04 Health Business Dev Gel hydratant, médicament et composition cosmétique le contenant, procédé de préparation dudit gel.

Also Published As

Publication number Publication date
WO1997034580A1 (en) 1997-09-25

Similar Documents

Publication Publication Date Title
Liu et al. A moldable nanocomposite hydrogel composed of a mussel‐inspired polymer and a nanosilicate as a fit‐to‐shape tissue sealant
Khanlari et al. Bioadhesives: a review
KR970064597A (ko) 위장장애 또는 위산분해가 있는 약물의 직장투여용 조성물
Chonkar et al. Smart polymers in nasal drug delivery
BR9903345A (pt) Emplastro cosmético, farmacêutico ou dermatológico e conjunto
HUP9904174A2 (hu) Bőrön át történő adagoláshoz szánt gyógyszerkészítmények
DE69803940D1 (de) Ophthalmische zusammensetzungen mit verlängerte freisetzung enthaltend im wasser lösliche arzneistoffe
CA2149362A1 (en) Pharmaceutical composition based on guar gum coated with simethicone, inassociation with a neutralizing antacid
IL149572A0 (en) Film preparation for biphasic release of pharmacologically active or other substances
KR960700670A (ko) 거대분자 약물의 경점막 수송용 제형
ATE300286T1 (de) Gastroretentive pharmazeutische dosierungsformen mit gesteuerten abgaben
ATE17189T1 (de) 5-asa enthaltende orale verabreichungsform mit verzoegerter wirkstofffreigabe.
KR910007518A (ko) 서방성 제제
BRPI0414017A8 (pt) pró-fármacos poliméricos de múltiplos braços
NO993195L (no) Blanding for administrasjon av medikamenter
BG102438A (en) Medicamentous form
EP0966966A3 (en) Nefazodone dosage form
NO20025759L (no) Formulering basert på heparin, glykosaminoglykan eller heparinoid, anvendelse av formuleringen og formuleringsbasen
EA200100118A1 (ru) Препарат в виде порошка для введения через слизистую оболочку, содержащий лекарственное средство с высокой молекулярной массой
EP1992336A3 (fr) Forme galénique pour la délivrance colique de principes actifs
DE69226950T2 (de) Kapsel mit Langzeitwirkung fuer die Adhäsion im Gastrointestinaltrakt
EP2108378A3 (en) Non-covalent bioconjugates useful for diagnosis and therapy
BR9914841A (pt) Sistema de terapia gastrorretentivo, expansìvel, com tempo de permanência no estÈmago prolongado
HUP0103543A2 (hu) Nyálkahártyán megtapadó hatóanyag bejuttató rendszerek és ezek alkalmazása állatok kezelésére
WO2003074086A1 (fr) Matrice liquide a transfert de phase in vivo, et preparations liquides orales

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application